乌司奴单抗在生物制剂初治银屑病关节炎患者中的疗效:按既往治疗暴露与病程分析
基于PSUMMIT 1和PSUMMIT 2两项III期随机对照试验的事后分析,纳入747例TNF抑制剂初治的活动性银屑病关节炎患者,评估乌司奴单抗45mg或90mg与安慰剂相比在第24周的疗效。结果显示,无论既往是否暴露于甲氨蝶呤或其他csDMARDs,乌司奴单抗组ACR20/50/70应答、DAS28-CRP应答及缓解率均高于安慰剂组,附着点炎和指炎完全缓解率亦更高。ACR应答率在病程<1年、≥1至<3年及≥3年患者中相似。
要点
- 乌司奴单抗在TNF初治PsA患者中第24周ACR20/50/70应答优于安慰剂,不受既往csDMARDs暴露影响。
- 乌司奴单抗组附着点炎和指炎完全缓解率高于安慰剂,且在各既往治疗亚组中一致。
- ACR应答率在病程<1年、≥1至<3年及≥3年患者中相似。
核心结论
- 乌司奴单抗治疗TNF初治PsA患者第24周临床应答优于安慰剂,且不受既往治疗暴露和病程影响。
研究设计与样本
- PSUMMIT 1和PSUMMIT 2为III期随机安慰剂对照试验,纳入活动性PsA≥6个月且对csDMARDs和/或NSAIDs(PSUMMIT 1)或csDMARDs、NSAIDs和/或抗TNF药物(PSUMMIT 2)应答不佳的成人患者。
- 患者随机接受皮下注射安慰剂、乌司奴单抗45mg或90mg,第0、4周及此后每12周给药;本分析为事后分析,共纳入747例TNF初治患者。
主要发现
- 第24周,在全部TNF初治、甲氨蝶呤初治(179例)及全部csDMARDs初治(146例)三个人群中,乌司奴单抗组达到ACR20/ACR50/ACR70应答、DAS28-CRP应答及DAS28-CRP缓解的比例均高于安慰剂组,组间差异相似。
- 第24周,乌司奴单抗组附着点炎和指炎完全缓解的比例在三个人群中均高于安慰剂组。
- 第24周总van der Heijde-Sharp评分较基线的平均变化在乌司奴单抗组通常小于安慰剂组,但仅在全部TNF初治人群中具有统计学显著性。
- 病程<1年、≥1至<3年及≥3年的TNF初治患者ACR20/ACR50/ACR70应答率相似。
关键数值与推荐
- 主要疗效评估指标为第24周ACR20/ACR50/ACR70应答率及基于C反应蛋白的28关节疾病活动度评分(DAS28-CRP)应答与缓解。
- 放射学进展采用总van der Heijde-Sharp评分评估,附着点炎和指炎亦在第24周评估。
临床怎么用
- 对于TNF初治的活动性PsA患者,乌司奴单抗可作为一线生物制剂选择,其疗效不受既往csDMARDs暴露或病程长短的明显影响。
局限性
- 本分析为事后分析,放射学进展的组间差异仅在全部TNF初治人群中具有统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy of ustekinumab by prior treatment exposure and disease duration in tumour necrosis factor inhibitor (TNF)-naïve patients with psoriatic arthritis (PsA) in the PSUMMIT 1 and PSUMMIT 2 studies. METHODS: In the phase 3, randomised, placebo-controlled PSUMMIT 1 and PSUMMIT 2 studies, adults with active PsA for ≥6 months despite conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and/or non-steroidal anti-inflammatory drugs (NSAIDs) (PSUMMIT 1) or csDMARDs, NSAIDs and/or anti-TNF agents (PSUMMIT 2) were enrolled. Patients were randomised to subcutaneous injections of placebo, ustekinumab 45 mg or ustekinumab 90 mg at weeks 0 and 4 and every 12 weeks. Efficacy was assessed at week 24 using the American College of Rheumatology criteria and 28-joint count disease activity score using C reactive protein (DAS28-CRP); radiographical progression, enthesitis, and dactylitis were also assessed in this post hoc analysis. RESULTS: A total of 747 patients were included; all 747 were TNF-naïve, of which, 179 were methotrexate-naïve and TNF-naïve, and 146 were all csDMARD-naïve and TNF-naïve. At week 24, greater proportions of ustekinumab-treated patients had ≥20%/50%/70% improvement in American College of Rheumatology criteria (ACR20/ACR50/ACR70) responses, DAS28-CRP response and DAS28-CRP remission versus placebo in all three prior-treatment populations, with similar differences between treatment groups. Greater proportions of ustekinumab-treated patients also had complete resolution of enthesitis and dactylitis at week 24 across the three prior-treatment populations. Mean changes from baseline in total van der Heijde-Sharp Score at week 24 were generally smaller for ustekinumab-treated patients versus placebo but were statistically significant only in the full TNF-naïve population. Response rates for ACR20/ACR50/ACR70 were similar for TNF-naïve patients with PsA durations of <1 year, ≥1 to <3 years, and ≥3 years. CONCLUSION: Ustekinumab-treated patients demonstrated greater clinical response at week 24 compared with placebo regardless of prior treatment exposure and PsA disease duration.
引用
- McInnes IB, Chakravarty SD, Apaolaza I, et al. Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2. RMD Open. 2019. PMID: 31565242. doi:10.1136/rmdopen-2019-000990
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。